Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023

October 30th 2024

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy

Your daily dose of the clinical news you may have missed.

October 29th 2024

ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 Years / image credit ©CDC

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

FDA Updates Flublok Label with Safety Data for Pregnant Individuals

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

Related Content

October 30th 2024

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy

Your daily dose of the clinical news you may have missed.

October 29th 2024

ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

FDA Updates Flublok Label with Safety Data for Pregnant Individuals

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.